Compumedics Limited

ASX:CMP Stock Report

Market Cap: AU$49.9m

Compumedics Management

Management criteria checks 4/4

Compumedics' CEO is David Burton, appointed in Jan 1987, has a tenure of 39.42 years. total yearly compensation is A$254.53K, comprised of 89.7% salary and 10.3% bonuses, including company stock and options. directly owns 49.17% of the company’s shares, worth A$24.56M. The average tenure of the management team and the board of directors is 26.4 years and 3.7 years respectively.

Key information

David Burton

Chief executive officer

AU$254.5k

Total compensation

CEO salary percentage89.69%
CEO tenure39.4yrs
CEO ownership49.2%
Management average tenure26.4yrs
Board average tenure3.7yrs

Recent management updates

Analysis Article • Oct 24

This Is Why Compumedics Limited's (ASX:CMP) CEO Compensation Looks Appropriate

Key Insights Compumedics to hold its Annual General Meeting on 31st of October CEO David Burton's total compensation...

Recent updates

Analysis Article • Jan 29

Compumedics Limited's (ASX:CMP) Price Is Right But Growth Is Lacking After Shares Rocket 26%

The Compumedics Limited ( ASX:CMP ) share price has done very well over the last month, posting an excellent gain of...
Analysis Article • Oct 16

Compumedics Limited's (ASX:CMP) Price Is Right But Growth Is Lacking After Shares Rocket 29%

The Compumedics Limited ( ASX:CMP ) share price has done very well over the last month, posting an excellent gain of...
Analysis Article • Oct 07

Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt Burden

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jul 28

Even With A 25% Surge, Cautious Investors Are Not Rewarding Compumedics Limited's (ASX:CMP) Performance Completely

Compumedics Limited ( ASX:CMP ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...
Analysis Article • May 27

Does Compumedics (ASX:CMP) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Mar 30

Compumedics Limited (ASX:CMP) Held Back By Insufficient Growth Even After Shares Climb 29%

Compumedics Limited ( ASX:CMP ) shareholders have had their patience rewarded with a 29% share price jump in the last...
Analysis Article • Feb 06

Compumedics Limited's (ASX:CMP) Subdued P/S Might Signal An Opportunity

With a price-to-sales (or "P/S") ratio of 1x Compumedics Limited ( ASX:CMP ) may be sending very bullish signals at the...
Analysis Article • Oct 24

This Is Why Compumedics Limited's (ASX:CMP) CEO Compensation Looks Appropriate

Key Insights Compumedics to hold its Annual General Meeting on 31st of October CEO David Burton's total compensation...
Analysis Article • Jun 17

Further Upside For Compumedics Limited (ASX:CMP) Shares Could Introduce Price Risks After 38% Bounce

Compumedics Limited ( ASX:CMP ) shareholders would be excited to see that the share price has had a great month...
Analysis Article • Mar 07

Returns On Capital Signal Difficult Times Ahead For Compumedics (ASX:CMP)

When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
Analysis Article • Nov 03

We Think Compumedics (ASX:CMP) Has A Fair Chunk Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • May 27

Is Compumedics (ASX:CMP) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Jan 25

Compumedics (ASX:CMP) Could Be At Risk Of Shrinking As A Company

If we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? A business...
Analysis Article • Oct 19

Some Shareholders May Object To A Pay Rise For Compumedics Limited's (ASX:CMP) CEO This Year

The disappointing performance at Compumedics Limited ( ASX:CMP ) will make some shareholders rather disheartened. At...
Analysis Article • Oct 14

Compumedics (ASX:CMP) Seems To Use Debt Quite Sensibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • May 02

Is Compumedics (ASX:CMP) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Dec 08

Compumedics (ASX:CMP) May Have Issues Allocating Its Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Analysis Article • Aug 09

Compumedics (ASX:CMP) Will Want To Turn Around Its Return Trends

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Analysis Article • Jun 10

Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt Burden

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • May 06

Returns On Capital Signal Tricky Times Ahead For Compumedics (ASX:CMP)

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
Analysis Article • Feb 25

These 4 Measures Indicate That Compumedics (ASX:CMP) Is Using Debt Extensively

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Dec 01

How Much Did Compumedics'(ASX:CMP) Shareholders Earn From Share Price Movements Over The Last Year?

It is doubtless a positive to see that the Compumedics Limited (ASX:CMP) share price has gained some 32% in the last...

CEO Compensation Analysis

How has David Burton's remuneration changed compared to Compumedics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

AU$113k

Sep 30 2025n/an/a

-AU$577k

Jun 30 2025AU$255kAU$228k

-AU$1m

Mar 31 2025n/an/a

-AU$1m

Dec 31 2024n/an/a

-AU$2m

Sep 30 2024n/an/a

-AU$965k

Jun 30 2024AU$253kAU$228k

-AU$338k

Mar 31 2024n/an/a

AU$447k

Dec 31 2023n/an/a

AU$1m

Sep 30 2023n/an/a

-AU$2m

Jun 30 2023AU$252kAU$228k

-AU$6m

Mar 31 2023n/an/a

-AU$6m

Dec 31 2022n/an/a

-AU$6m

Sep 30 2022n/an/a

-AU$2m

Jun 30 2022AU$251kAU$228k

AU$1m

Mar 31 2022n/an/a

AU$663k

Dec 31 2021n/an/a

-AU$31k

Sep 30 2021n/an/a

AU$484k

Jun 30 2021AU$244kAU$223k

AU$998k

Mar 31 2021n/an/a

-AU$2m

Dec 31 2020n/an/a

-AU$5m

Sep 30 2020n/an/a

-AU$5m

Jun 30 2020AU$237kAU$217k

-AU$6m

Mar 31 2020n/an/a

-AU$1m

Dec 31 2019n/an/a

AU$3m

Sep 30 2019n/an/a

AU$4m

Jun 30 2019AU$250kAU$228k

AU$4m

Compensation vs Market: David's total compensation ($USD175.84K) is below average for companies of similar size in the Australian market ($USD319.37K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Burton (67 yo)

39.4yrs
Tenure
AU$254,532
Compensation

Dr. David Burton, Ph.D. founded Compumedics Ltd. in 1987 and serves as its Executive Chairman and Chief Executive Officer. Dr. Burton serves as Executive Chairman and Chief Executive Officer of Compumedics...

Leadership Team

NamePositionTenureCompensationOwnership
David Burton
Founder39.4yrsAU$254.53k49.17%
A$ 24.6m
David Lawson
CFO, Company Secretary & Executive Director26.4yrsAU$407.58k1.74%
A$ 867.7k
Warwick Freeman
Chief Technology Officerno dataAU$344.93k0.041%
A$ 20.5k
Kerry Hubick
Legal Counsel and Trademarkno dataAU$81.25kno data
Michael Stone
Chief Commercial Officer - US operationsno datano datano data
26.4yrs
Average Tenure

Experienced Management: CMP's management team is seasoned and experienced (26.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Burton
Founderno dataAU$254.53k49.17%
A$ 24.6m
David Lawson
CFO, Company Secretary & Executive Director12.7yrsAU$407.58k1.74%
A$ 867.7k
Christopher Barrys
Non-Executive Directorless than a yearno datano data
Rodney North
Non-Executive Director3.7yrsAU$30.00k0.0010%
A$ 499.4
3.7yrs
Average Tenure
61yo
Average Age

Experienced Board: CMP's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/24 06:37
End of Day Share Price 2026/06/24 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Compumedics Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ian MartinNew Street Research LLP
Paul JenszPAC Partners Securities Pty. Ltd.
Stephen ScottTaylor Collison Limited